Francesco Tedesco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8359781/publications.pdf

Version: 2024-02-01

106 papers	8,456 citations	47006 47 h-index	46799 89 g-index
110 all docs	110 docs citations	110 times ranked	9554 citing authors

#	Article	IF	Citations
1	Distinct Roles of Classical and Lectin Pathways of Complement in Preeclamptic Placentae. Frontiers in Immunology, 2022, 13, .	4.8	6
2	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	6.5	127
3	Î²2 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 0271678X2098455.	4.3	8
4	Memories of Bob Simâ€"Genius Complementologist and Cheerful Travel Companion. Viruses, 2021, 13, 1068.	3.3	2
5	An allosteric redox switch in domain V of Î²2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. Journal of Biological Chemistry, 2021, 297, 100890.	3.4	10
6	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines, 2021, 9, 1003.	3.2	44
7	The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. Frontiers in Immunology, 2020, 11, 2084.	4.8	30
8	Complement Activation and Thrombin Generation by MBL Bound to Î²2-Glycoprotein I. Journal of Immunology, 2020, 205, 1385-1392.	0.8	16
9	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Frontiers in Immunology, 2020, 11, 584241.	4.8	137
10	Complement activation in patients with COVID-19: AÂnovel therapeutic target. Journal of Allergy and Clinical Immunology, 2020, 146, 215-217.	2.9	210
11	The J-elongated conformation of Î²2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. Journal of Biological Chemistry, 2020, 295, 10794-10806.	3.4	20
12	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. Journal of Autoimmunity, 2019, 103, 102288.	6.5	33
13	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 773.	4.8	28
14	Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmunity Reviews, 2019, 18, 561-563.	5.8	25
15	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica, 2019, 104, 819-826.	3.5	40
16	Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. Frontiers in Immunology, 2018, 9, 2664.	4.8	165
17	Complement as a Biological Tool to Control Tumor Growth. Frontiers in Immunology, 2018, 9, 2203.	4.8	31
18	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Frontiers in Immunology, 2018, 9, 1388.	4.8	51

#	Article	IF	Citations
19	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nature Reviews Rheumatology, 2018, 14, 433-440.	8.0	95
20	C1q: A fresh look upon an old molecule. Molecular Immunology, 2017, 89, 73-83.	2.2	188
21	Alternative functions of the complement protein C1q at embryo implantation site. Journal of Reproductive Immunology, 2017, 119, 74-80.	1.9	29
22	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Frontiers in Immunology, 2017, 8, 1093.	4.8	20
23	Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth. Frontiers in Immunology, 2017, 8, 1559.	4.8	44
24	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood, 2016, 127, 365-367.	1.4	67
25	Complement component C1q <scp>as</scp> potential diagnostic but not predictive marker of preeclampsia. American Journal of Reproductive Immunology, 2016, 76, 475-481.	1.2	30
26	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nature Communications, 2016, 7, 10346.	12.8	224
27	European Union funded project on the development of a whole complement deficiency screening ELISAâ€"A story of success and an exceptional manager: Mohamed R. Daha. Molecular Immunology, 2015, 68, 63-66.	2.2	3
28	Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. Journal of Immunology, 2015, 195, 5602-5607.	0.8	30
29	C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4209-4214.	7.1	140
30	A nonâ€"complement-fixing antibody to Î²2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 2014, 123, 3478-3487.	1.4	120
31	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
32	Role of the B1 Bradykinin Receptor and gC1qR/p33 in Angioedema. Immunology and Allergy Clinics of North America, 2013, 33, 535-544.	1.9	2
33	Orchestration of Inflammation and Adaptive Immunity in Borrelia burgdorferiâ€"Induced Arthritis by Neutrophilâ€Activating Protein A. Arthritis and Rheumatism, 2013, 65, 1232-1242.	6.7	32
34	Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. PLoS ONE, 2013, 8, e58696.	2.5	24
35	Chemerin Regulates NK Cell Accumulation and Endothelial Cell Morphogenesis in the Decidua during Early Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3603-3612.	3.6	75
36	MBL Interferes with Endovascular Trophoblast Invasion in Pre-Eclampsia. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	19

#	Article	IF	Citations
37	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis and Rheumatism, 2012, 64, 2559-2567.	6.7	39
38	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
39	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nature Reviews Rheumatology, 2011, 7, 330-339.	8.0	482
40	In vivo distribution of Î²2 glycoprotein I under various pathophysiologic conditions. Blood, 2011, 118, 4231-4238.	1.4	113
41	Cross-talk between the complement and the kinin system in vascular permeability. Immunology Letters, 2011, 140, 7-13.	2.5	56
42	Complement activation in animal and human pregnancies as a model for immunological recognition. Molecular Immunology, 2011, 48, 1621-1630.	2.2	71
43	Inhibiting the C5â€“C5a receptor axis. Molecular Immunology, 2011, 48, 1631-1642.	2.2	272
44	An insight into normal and pathological pregnancies using large-scale microarrays: lessons from microarrays. Journal of Reproductive Immunology, 2011, 89, 163-172.	1.9	7
45	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
46	Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opinion on Biological Therapy, 2010, 10, 863-873.	3.1	16
47	An Alternative Role of C1q in Cell Migration and Tissue Remodeling: Contribution to Trophoblast Invasion and Placental Development. Journal of Immunology, 2010, 185, 4420-4429.	0.8	135
48	Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma. Current Clinical Pharmacology, 2010, 5, 246-250.	0.6	6
49	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. Cancer Research, 2009, 69, 4001-4009.	0.9	153
50	Complement production by trophoblast cells at the feto-maternal interface. Journal of Reproductive Immunology, 2009, 82, 119-125.	1.9	50
51	Early regulators in abortion and implications for a preeclampsia model. Journal of Reproductive Immunology, 2009, 82, 132-141.	1.9	26
52	Bilirubin inhibits the TNFÎ±-related induction of three endothelial adhesion molecules. Biochemical and Biophysical Research Communications, 2009, 386, 338-344.	2.1	76
53	Complement in human diseases: Lessons from complement deficiencies. Molecular Immunology, 2009, 46, 2774-2783.	2.2	250
54	Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2009, 124, 1303-1310.e4.	2.9	94

#	Article	IF	Citations
55	C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. Blood, 2009, 113, 3640-3648.	1.4	44
56	Monocytes/Macrophages Are the Major Targets of the CCL3 Chemokine Produced by CD38+CD49d+ Chronic Lymphocytic Leukemia Cells.. Blood, 2009, 114, 2350-2350.	1.4	0
57	ABSTRACTS: 12â€ The complement component C1q: A novel angiogenic factor?. American Journal of Reproductive Immunology, 2008, 60, 89-89.	1.2	0
58	Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. Blood, 2008, 111, 3108-3115.	1.4	222
59	Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Molecular Immunology, 2008, 45, 2629-2640.	2.2	82
60	Endothelial cells are a target of both complement and kinin system. International Immunopharmacology, 2008, 8, 143-147.	3.8	24
61	Inherited complement deficiencies and bacterial infections. Vaccine, 2008, 26, I3-I8.	3.8	32
62	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology, 2008, 48, 293-298.	1.9	29
63	An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. Current Pharmaceutical Design, 2008, 14, 2023-2039.	1.9	20
64	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. Transplantation, 2008, 86, 1445-1451.	1.0	24
65	In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. Molecular Imaging, 2008, 7, 7290.2008.00028.	1.4	29
66	CCL3 and CCL4, the Major Chemokines Produced by CD38+ Chronic Lymphocytic Leukemia Cells, Facilitate Microenvironmental Interactions of Neoplastic Cells Via the CD49d/VCAM Pair.. Blood, 2008, 112, 1055-1055.	1.4	0
67	In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Molecular Imaging, 2008, 7, 272-82.	1.4	14
68	Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2319-2324.	7.1	171
69	In vivoTargeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab. Cancer Research, 2007, 67, 10556-10563.	0.9	141
70	The Neutrophil-Activating Protein of Helicobacter pylori Crosses Endothelia to Promote Neutrophil Adhesion In Vivo. Journal of Immunology, 2007, 178, 1312-1320.	0.8	87
71	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110, 536-543.	1.4	121
72	Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis and Rheumatism, 2007, 56, 1187-1197.	6.7	29

#	Article	IF	Citations
73	Complement as effector system in cancer immunotherapy. Immunology Letters, 2007, 111, 6-13.	2.5	72
74	Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity, 2006, 39, 417-428.	2.6	87
75	The complement system in the pathophysiology of pregnancy. Molecular Immunology, 2006, 43, 68-77.	2.2	156
76	EMILIN1 represents a major stromal element determining human trophoblast invasion of the uterine wall. Journal of Cell Science, 2006, 119, 4574-4584.	2.0	62
77	Complement Activated by Chimeric Antiâ€“Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. Cancer Research, 2006, 66, 3876-3883.	0.9	36
78	Complement in autoimmunity and tissue injury. Autoimmunity, 2006, 39, 355-356.	2.6	1
79	Thrombus formation induced by antibodies to Î²2-glycoprotein I is complement dependent and requires a priming factor. Blood, 2005, 106, 2340-2346.	1.4	324
80	Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. European Journal of Immunology, 2005, 35, 2175-2183.	2.9	92
81	Platelet-Activating Factor and Kinin-Dependent Vascular Leakage as a Novel Functional Activity of the Soluble Terminal Complement Complex. Journal of Immunology, 2004, 173, 6921-6927.	0.8	85
82	VE-cadherin is a critical molecule for trophoblast?endothelial cell interaction in decidual spiral arteries. Experimental Cell Research, 2004, 303, 101-13.	2.6	75
83	Terminal Complement Complex: Regulation of Formation and Pathophysiological Functions. , 2004, , 97-127.		8
84	Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. European Journal of Immunology, 2003, 33, 1260-1270.	2.9	42
85	Serum-Resistant Strains of Borrelia burgdorferi Evade Complement-Mediated Killing by Expressing a CD59-Like Complement Inhibitory Molecule. Journal of Immunology, 2003, 170, 3214-3222.	0.8	92
86	Placental Trophoblast and Endothelial Cells as Target of Maternal Immune Response. Autoimmunity, 2003, 36, 11-18.	2.6	23
87	Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood, 2002, 99, 185-192.	1.4	72
88	The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. European Journal of Immunology, 2002, 32, 2773-2782.	2.9	40
89	The membrane attack complex of complement induces caspase activation and apoptosis. European Journal of Immunology, 2002, 32, 783.	2.9	136
90	The complement system at the feto-maternal interface: friend or foe?. American Journal of Reproductive Immunology, 2002, 48, 142-143.	1.2	0

#	Article	IF	Citations
91	The membrane attack complex of complement induces caspase activation and apoptosis. , 2002, 32, 783.		1
92	Hepatocyte Nuclear Factor 1Î± Controls the Expression of Terminal Complement Genes. Journal of Experimental Medicine, 2001, 194, 1683-1690.	8.5	19
93	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 2000, 95, 3900-3908.	1.4	523
94	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 2000, 95, 3900-3908.	1.4	124
95	C8. , 2000, , 123-130.		0
96	I. Adrenal Cortex and Steroid 21-Hydroxylase Autoantibodies in Adult Patients with Organ-Specific Autoimmune Diseases: Markers of Low Progression to Clinical Addisonâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 932-938.	3.6	109
97	The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity. Journal of Experimental Medicine, 1997, 185, 1619-1628.	8.5	289
98	Experimental Induction of Myelin Changes by Anti-MAG Antibodies and Terminal Complement Complex. Journal of Neuropathology and Experimental Neurology, 1995, 54, 96-104.	1.7	45
99	Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. Kidney International, 1995, 47, 829-836.	5.2	32
100	Decidual-trophoblast interactions: decidual lymphoid cell populations in basal and parietal decidua. Journal of Reproductive Immunology, 1995, 28, 165-171.	1.9	14
101	Effect of cytokines on the secretion of the fifth and eighth complement components by HepG2 cells. International Journal of Clinical and Laboratory Research, 1994, 24, 45-48.	1.0	21
102	Inherited Deficiencies of the Terminal Complement Components. International Reviews of Immunology, 1993, 10, 51-64.	3.3	32
103	An immunohistochemical study of leucocytes in human endometrium, first and third trimester basal decidua. Journal of Reproductive Immunology, 1993, 23, 41-49.	1.9	81
104	An electrophysiological study of the effects of myasthenia gravis sera and complement on rat isolated muscle fibres. Journal of Neuroimmunology, 1993, 45, 155-162.	2.3	5
105	Complement-Mediated Demyelination in Patients with IgM Monoclonal Gammopathy and Polyneuropathy. New England Journal of Medicine, 1990, 322, 649-652.	27.0	173
106	Î² Chain deficiency in three patients with dysfunctional C8 molecules. Molecular Immunology, 1983, 20, 47-51.	2.2	8